Citations

Clear

426 citation(s) found for "ST, Reza".

Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis
Kazemi, Mir Salar, Kazemi-Lomedasht, Fatemeh, Mahjoobi, Golnoosh, Safi, Sare , Ashrafi, Sadra , Ahmadieh, Hamid, Shoari, Alireza , Kazemi-Lomedasht, Fatemeh , Kanavi, Mozhgan Rezaei , Cohan, Reza Ahangari , Ahmadieh, Hamid , Behdani, Mahdi

Mayo Clinic

Biomolecules | May 25, 2026 | Volume: 16 | Issue: 6 | Pages: 772

10.3390/biom16060772 | PMID 42352241 Get It

Current treatments for choroidal neovascularization (CNV) and its associated subretinal fibrosis (SRF), major causes of vision loss, are limited by the need for frequent intravitreal injections and the emergence of drug resistance. This study evaluated the safety and efficacy of the intravitreal administration of engineered humanized anti-vascular endothelial growth factor Nanobodies, including a wild-type Nanobody (WHNb) and two mutated variants (MHNb136 and MHNb256), in a rat model of laser-induced CNV and associated SRF. Safety was assessed through in vivo electrophysiological and histopathological analyses following intravitreal injection of Nanobodies at doses of 12.5, 25, 50, and 100 µg. Efficacy was evaluated in rat models of laser-induced CNV and SRF using double immunohistochemistry for isolectin B4 and anti-collagen type I on sclerochoroidal flat mounts. Mean CNV and SRF areas in Nanobody-treated groups were compared with those in bevacizumab-treated and sham control groups. None of the Nanobodies showed retinal toxicity in safety assessments. Compared with bevacizumab, MHNb136 and MHNb256 reduced the CNV area by 1.72-fold and 1.8-fold, respectively (both p < 0.0001), whereas WHNb showed an effect nearly identical to that of bevacizumab. In addition, 12.5 µg MHNb136 and 100 µg MHNb256 reduced the SRF area by 1.3-fold (p = 0.047) and 1.6-fold (p = 0.0007), respectively, relative to bevacizumab. For CNV reduction, 12.5 µg MHNb136 was comparable to 25 µg MHNb256; both outperformed bevacizumab. For SRF reduction, 12.5 µg MHNb136 was more effective than bevacizumab and comparable to 100 µg MHNb256. These findings suggest that 12.5 µg MHNb136 may represent a cost-effective bioengineered Nanobody candidate for future clinical studies.
Comparison of Conventional versus Abbreviated MR Enterography: Assessing Disease Activity and Complications in Crohn Disease
Rimola, Jordi , Anupindi, Sudha, Capozzi, Nunzia , Dane, Bari, Flicek, Kristina T. , Fernández-Clotet, Agnès , Grajo, Joseph R. , Huang, Chenchan , Jaffe, Tracy A. , Ordás, I, Roca, Andreu, Saavedra, Carolina, Anupindi, Sudha A , Dane, Bari , Jaffe, Tracy , De Kock, Isabelle , Ordás, Ingrid , Radmard, Amir Reza , Roca, Andreu , Scharitzer, Martina , Dillman, Jonathan R , Rimola, Jordi , Anupindi, Sudha A. , Fernandez-Clotet, Agnes , Grajo, Joseph R. , Ordás, Íngrid , Radmard, Amir Reza

Mayo Clinic

Radiology | May 12, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.252039 | PMID 42117993 Get It

In participants with Crohn disease (CD), an abbreviated MR enterography (MRE) protocol demonstrated similar interreader agreement to contrast-enhanced MRE and high intrareader concordance for detecting active CD and related complications.
LOOPS for thought: identifying gastrointestinal pathology on transthoracic echocardiography
Elsayed, Ahmed Magdy , Arsanjani, R A, Naqvi, Tasneem Z. , Magdy, Ahmed , Naqvi, Tasneem Z , Arsanjani, Reza

Mayo Clinic

European Heart Journal - Case Reports | May 8, 2026 | Volume: 10 | Issue: 5 | Pages: No page available

10.1093/ehjcr/ytag339 | PMID 42181818 Get It

Abstract Background Transthoracic echocardiography (TTE) is the most commonly used modality for the diagnosis and follow-up of cardiac diseases. During routine TTE, surrounding extracardiac structures are often visualized, including the lungs, pleural spaces, oesophagus, diaphragm, and sub-diaphragmatic structures such the liver, stomach, bowel, and abdominal aorta. Pathologic conditions affecting these organs may exert extrinsic compression on the cardiac chambers, leading to diagnostic uncertainty or mimicking cardiac disease by producing symptoms, such as dyspnoea, fatigue, chest pain, or palpitations. Case summary We describe five patients who underwent routine TTE and were incidentally found to have unsuspected gastrointestinal abnormalities. The findings subsequently confirmed by other imaging modalities included hiatal hernia, distended bowel loops, oesophageal carcinoma, and oesophageal varices. Reporting of these findings impacted the diagnosis and management of the cases. Conclusion Awareness of the sonographic appearance of gastrointestinal during TTE is essential, as these findings may represent clinically significant pathology that mimics or contributes to cardiac symptoms. Recognition of such findings may be enhanced by modified echocardiographic views, with confirmatory evaluation using chest radiography, computed tomography, or gastrointestinal endoscopy as appropriate
Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications
Hafez, Abdelrahman , Farina, Juan M. , Awad, Kamal, Pietri, Milagros Pereyra, Scalia, Isabel G. , Sheashaa, Hesham, Abdelfattah, Fatmaelzahraa , Razaghi, Mahshad , Ahmed, Sherif, Ibrahim, Ramzi, Simper, David, Lester, Steven J., Tamarappoo, Balaji, Ayoub, C A, Arsanjani, R A, Arsanjani, Reza , Pereyra, Milagros , Pereyra, Milagros , Sheashaa, Hesham , Abdelfattah, Fatmaelzahraa , Arsanjani, Reza , Farina, Juan M , Scalia, Isabel G , Awad, Kamal , Ahmed, Sherif , Ibrahim, Ramzi

Mayo Clinic

Journal of Personalized Medicine | May 6, 2026 | Volume: 16 | Issue: 5 | Pages: 254

10.3390/jpm16050254 | PMID 42188348 Get It

Coronary microvascular dysfunction (CMD) has emerged as a crucial contributor to cardiovascular morbidity and mortality, particularly in patients with ischemia and non-obstructive coronary arteries (INOCA). The condition arises from a complex interplay of structural and functional abnormalities within the small coronary vessels, driven by underlying molecular mechanisms including endothelial nitric oxide synthase (eNOS) uncoupling, oxidative stress, and chronic inflammation. Lipid metabolism plays a central role in this pathology, especially in the setting of elevated low-density lipoprotein cholesterol (LDL-C). Furthermore, the protective capacity of high-density lipoprotein (HDL) is increasingly understood to depend on its functionality rather than absolute levels, as it can become dysfunctional and pro-inflammatory in pathological states. Emerging evidence has identified lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins as significant, independent contributors to microvascular injury. Comprehensive clinical assessment of microvascular dysfunction therefore requires integration of advanced lipid profiling, including apolipoprotein B (ApoB), [Lp(a)], and the triglyceride-glucose (TyG) index with invasive and non-invasive measures of coronary flow reserve to more precisely stratify risk. In this narrative review, we synthesize current observational, mechanistic, and early interventional data linking diverse lipid phenotypes to coronary microvascular dysfunction. We propose a concept of lipid-driven CMD endotypes, such as ApoB-/particle overload, dysfunctional HDL, Lp(a)-mediated risk, and metabolic/TyG-high states, and map these to a practical, mechanism-informed management framework. While intensive LDL-C lowering with high-intensity statins and combination therapy remains guideline-directed care for high-risk patients, evidence for dedicated microvascular benefit from newer lipid and cardiometabolic agents is still largely hypothesis-generating. A personalized approach that aligns lipid phenotyping, CMD endotyping, and existing guideline-based therapies may help refine risk assessment and inform future trials.
Optimal Timing of Coronary Artery Bypass Grafting in Patients with NSTEMI – A National Study from The United States
Tran, Viet Nghi, Pham, Hoang Nhat, Ibrahim, Ramzi, Truong, Hong Hieu, Abdelnabi, Mahmoud, Dhindsa, Amreen , Le, Pham Thao Vy, Nguyen, Doan Ngoc Chau, Jamal, Aisha, Tran, Phillip, Nguyen, Thach, Chahal, Anwar, Lee, Kwan S, Arsanjani, Reza, Singh, Amitoj, Tran, Viet Nghi, Pham, Hoang Nhat , Ibrahim, Ramzi , Abdelnabi, Mahmoud , Tran, Phillip , Chahal, C. Anwar A. , Arsanjani, Reza , Singh, Amitoj

Mayo Clinic

Marshall Journal of Medicine | May 1, 2026 | Volume: 12 | Issue: 2 | Pages: No page available

10.33470/2379-9536.1509 Get It

Background: The timing of coronary artery bypass grafting (CABG) in patients with non-ST-elevation myocardial infarction (NSTEMI) may critically impact clinical outcomes, yet the ideal surgical window remains unclear. We aimed to evaluate the association between time-to-CABG and in-hospital outcomes among NSTEMI admissions undergoing CABG. Methods: This retrospective cohort study utilized the US National Inpatient Sample database from 2017 to 2021 to evaluate the association between time-to-CABG and key in-hospital outcomes, including mortality, cardiac arrest, cardiogenic shock, ischemic stroke, acute kidney injury, and blood transfusion rates, while assessing length of stay (LOS) and hospital charges exclusively among survivors. Adult admissions with principal diagnosis of NSTEMI who underwent CABG without prior interhospital transfer were grouped by the calendar day of CABG from admission (0, 1, 2, 3, 4, 5, 6, and ≥7). Multivariate regression models were used to assess the outcomes across these eight groups. Results: Of 142,200 included admissions, same-day CABG (hospital day 0) was associated with the highest rates of in-hospital mortality, cardiac arrest, cardiogenic shock, and ischemic stroke. The adjusted odds of mortality, cardiac arrest, and cardiogenic shock were lower among admissions undergoing CABG between days 2 and 5. Likewise, the adjusted odds of ischemic stroke were lowest when CABG occurred on days 2 to 4. The odds of AKI increased when CABG was delayed beyond day 6, whereas blood transfusion rates showed no statistically significant association with time-to-CABG. Among survivors, LOS and hospital charges progressively increased with delayed CABGs. Conclusions: Among NSTEMI admissions undergoing CABG, CABG performed on hospital days 2 to 4 was associated with lower adjusted odds of several adverse in-hospital outcomes compared with same-day CABG. Further prospective studies are needed to validate these results and guide clinical decision-making.
Beyond Doppler: Scalable AI Detection of LVOT Obstruction in HCM
Crystal, Owen , Farina, Juan Maria M, Scalia, Isabel G. , Ayoub, C A, Park, H B, Arsanjani, R A, Lester, Steven J, Banerjee, Imon, Arsanjani, Reza , Park, Hyung‐Bok , Arsanjani, Reza , Scalia, Isabel G , Park, Hyung Bok , Farina, Juan M. , Etchegoyen, Cecilia Villa , Chollet, Laurève , Kim, Kyung An , Lester, Steven J., Banerjee, Imon

Mayo Clinic

No container title available | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.17.26351151 Get It

Abstract Background Accurate assessment of left ventricular outflow tract (LVOT) gradients is critical for hypertrophic cardiomyopathy (HCM) management, yet Doppler-based measurements are technically demanding and require expertise. Objective To develop a multi-view deep learning model capable of classifying LVOT obstruction (> 20mmHg) using routine 2D echocardiographic windows without reliance on Doppler imaging. Methods We trained and externally validated a cross-attention-based video-to-video fusion framework that integrated EchoPrime-derived video representations from three standard transthoracic echocardiographic views to classify LVOT gradients. Results Training was performed on a derivation cohort (N = 1833) from a tertiary care system in the United States, with model performance evaluated on an internal held-out test set (N = 275) and a Korean external validation cohort (N = 46). Single-view baselines showed limited discrimination (external AUROCs 0.47–0.70). Conversely, domain-specific foundational model (EchoPrime) achieved superior single-view performance (AUROCs 0.75–0.80 internal; 0.79–0.83 external), highlighting the importance of echo-specific pretraining and temporal modeling. The proposed multi-view fusion further enhanced predictive performance, with the late fusion model reaching an AUROC of 0.84 on the external cohort with significant population-shift. Conclusions These results suggest LVOT physiology is encoded in routine 2D imaging and can be leveraged for clinically relevant gradient classification without Doppler input- proposed AI-guided strategy demonstrates substantial cost savings compared with the screen-all approach. By integrating complementary spatial-temporal information across multiple views, our approach generalizes robustly across populations and may enable real-time decision support, extend LVOT assessment to portable or resource-limited settings, and complement Doppler-based evaluation for longitudinal HCM management.
Prognostic value of transaortic flow rate compared with ejection fraction and stroke volume index in low-gradient severe aortic stenosis
Allam, M A, Etchegoyen, Cecilia Villa , Sheashaa, Hesham, Rafie, Nikita , Ibrahim, Ramzi, Mahmoud, Ahmed K, Awad, K, Abdelnabi, Mahmoud, Sell-Dottin, Kristen, Lester, Steven J, Sweeney, John P, Ayoub, Chadi, Lee, K S, Fortuin, David F, Arsanjani, Reza, Villa Etchegoyen, Cecilia , Allam, Mohamed , Alsidawi, Said , Pathangey, Girish , Ibrahim, Ramzi , Farina, Juan M. , Mahmoud, Ahmed , Awad, Kamal , Abdelnabi, Mahmoud , Sell‐Dottin, Kristen , Lester, Steven J., Fortuin, David, Arsanjani, Reza

Mayo Clinic

Heart | April 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: heartjnl-2025-327594

10.1136/heartjnl-2025-327594 | PMID 41980805 Get It

Background In low-gradient severe aortic stenosis (AS), reduced left ventricular ejection fraction (LVEF <50%) is practically used to define low flow and prompt dobutamine stress echocardiography to discern pseudo-severe AS. In patients with preserved LVEF, stroke volume index (SVI) <35 mL/m² is typically used. However, both are volume-based surrogates. Transaortic flow rate (TAFR), calculated as stroke volume divided by left ventricular ejection time, may better reflect true flow. Nonetheless, comparative data between TAFR and established metrics remain limited. We aimed to evaluate the prognostic value of TAFR in symptomatic low-gradient severe AS. Methods We retrospectively identified patients with low-gradient severe AS (AVA ≤1 cm 2 and peak velocity (Vmax) <4 m/s or mean gradient (MG) <40 mm Hg) who underwent transcatheter aortic valve replacement at Mayo Clinic sites (2017–2023). The primary outcome was 1-year all-cause mortality. Survival was assessed using Kaplan-Meier and Cox proportional hazards models. Results Among 475 patients included (mean age 85±8 years; 49% women), 242 (51%) had TAFR <220 mL/s, 165 (35%) had EF <50%, and 221 (47%) had SVI <35 mL/m 2 . Low TAFR was significantly associated with higher 1-year mortality even after stratifying by EF or SVI. In multivariate analysis, TAFR was an independent predictor of mortality (HR 2.38; 95% CI 1.19 to 4.76, p=0.014) after adjusting for reduced LVEF, low SVI, gender, chronic kidney disease and mitral and tricuspid regurgitation. Conclusions In patients with symptomatic low-gradient severe AS, low TAFR, not SVI or LVEF, is independently associated with mortality and may offer more accurate measure of flow state for clinical staging.
Representation of Women in Atrial Fibrillation Clinical Trials: A Systematic Review
Ibrahim, Ramzi, Pham, Hoang Nhat, Kanaan, Christopher , Alhwarat, Buthainah, Sainbayar, Enkhtsogt , Soin, Sabrina , Ayoub, Chadi, Chieffo, Alaide , Sharma, Garima , Protheroe, Jo , Lee, JC, Arsanjani, Reza, Mamas, Mamas A., Sharma, Garima , Pham, Hoang Nhat , Ibrahim, Ramzi , Ibrahim, Ramzi , Nhat, Hoang , Ayoub, Chadi , Deshmukh, Abhishek J , Arsanjani, Reza , Lee, Kwan S , Mamas, Mamas , Sharma, Garima , Kanaan, Christopher N , Ibrahim, Ramzi , Arsanjani, Reza , Lee, Kwan , Mamas, Mamas A.

Mayo Clinic

Reviews in Cardiovascular Medicine | March 31, 2026 | Volume: 27 | Issue: 3 | Pages: No page available

10.31083/rcm47907 | PMID 41923740 Get It

Background: Disparities exist in the representation of genders in cardiovascular clinical trials. Atrial fibrillation (AF) is associated with significant morbidity and mortality; however, understanding regarding the representation of women in AF-related clinical trials remains limited. Therefore, this systematic review sought to evaluate the representation of women in AF-related clinical trials. Methods: We conducted a systematic review of clinical trials using the PubMed, Scopus, and EMBASE databases from 1996 to January 1st, 2024, focusing on AF-related lifestyle interventions, pharmacological treatments, catheter ablation, and device therapies for AF. Data extraction and analysis encompassed trial characteristics, participant demographics, and funding sources. The primary outcome was the prevalence of female enrollees, quantified through participation-to-prevalence ratios (PPRs). This was estimated overall and stratified by funding source, intervention type, and enrollment region. Results: Of the 103 clinical trials involving 218,322 participants (39.5% female), the PPR ranged from 0.00 to 1.73, with an average PPR of 1.03. Meanwhile, 43% of the trials exhibited female under-representation (PPR, <0.8). University-funded trials showed higher female enrollment (mean PPR, 0.951) compared to industry/government-funded trials (mean PPR, 0.800). No differences were observed in the representation of women when comparing enrollment regions or intervention types. Conclusions: Despite advancements in AF management, gender disparities persist in AF-related clinical trial representation, particularly in industry/government-funded studies compared to university-funded trials. Thus, addressing implicit biases and enforcing sex equality guidelines are critical steps toward more inclusive cardiovascular research.
Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis
Mahmoud, Ahmed K, Awad, Kamal, Sheashaa, Hesham, Kandil, Omneya , Farina, Juan M, Ibrahim, Ramzi, Abdelnabi, Mahmoud, Allam, Mohamed , Mital, Rohit , Shipman, Justin , Lester, Steven J, Ommen, Steve R, Geske, Jeffrey B, Patten, Richard D. , Ayoub, Chadi, Arsanjani, Reza, Mahmoud, Ahmed , Mahmoud, Ahmed K , Awad, Kamal , Alsidawi, Said , Ayoub, Chadi , Allam, Mohamed N , Awad, Kamal , Farina, Juan M. , Ibrahim, Ramzi , Abdelnabi, Mahmoud , Alsidawi, Said , Lester, Steven J., Ommen, Steve R. , Geske, Jeffrey B. , Arsanjani, Reza

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | March 26, 2026 | Volume: 12 | Issue: 5 | Pages: 731-739

10.1093/ehjqcco/qcag051 | PMID 41910632 Get It

Abstract Aims Obesity is linked with worse outcomes in hypertrophic cardiomyopathy (HCM). While both bariatric surgery (BS) and GLP-1 receptor agonists (GLP-1RA) promote weight loss and may improve cardiometabolic risk, their comparative outcomes in HCM remain unclear. Methods and results Adults with HCM and body mass index (BMI) ≥ 30 kg/m were divided into two cohorts: (i) GLP-1 RA users who never had BS, and (ii) BS patients who never received GLP-1 RA. Propensity score matching (1:1) was performed to balance demographics, comorbidities, and medications. Outcomes over 24 months include all-cause mortality, acute heart failure (HF) hospitalization, arrhythmias, change in BMI, and cardiovascular symptoms. Hazard ratios with 95% confidence intervals were estimated using Cox models. Of 5002 patients, 955 were included in each matched cohort after matching (mean age 54 ± 13 years, 70% female, BMI 40.0 kg/m). GLP-1 RA was associated with a significantly lower observed rate of all-cause mortality compared with BS (2.0% vs. 4.4%; HR 0.46; 95% CI 0.27–0.80; P = 0.004) and HF hospitalization (8.7% vs. 14.0%; HR 0.60; 95% CI 0.46–0.79; P &lt; 0.001). Similarly, GLP-1 RA use was associated with a lower incidence of composite cardiovascular outcomes (10.7% vs. 17.2%; HR 0.60; 95% CI 0.47–0.77; P &lt; 0.001). Rates of arrhythmia and cardiovascular symptoms were comparable between the two groups. BMI reduction was greater after bariatric surgery (−4.0 vs. −2.6 kg/m; P &lt; 0.001). Conclusion In obese patients with HCM, GLP-1 RA therapy was associated with lower all-cause mortality and fewer HF events compared with BS. Future studies are warranted to confirm our findings.